Biblio

Author Title [ Type

] Year

Filters: Author is Bittencourt, Henrique [Clear All Filters]

Journal Article

Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, de Moerloose B, Qayed M, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2022:JCO2200642.

Lachance S, Gomes MM, Bambace NM, Bittencourt H, Lepic K, Shafey M, Karpinski J, Guilcher GMT. Recognition of Hematopoietic Stem Cell Transplant and Cellular Therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focus Competence in Canada. Transplant Cell Ther. 2021.

Franck B, Woillard J-B, Théorêt Y, Bittencourt H, Demers E, Briand A, Marquet P, Lapeyraque A-L, Ovetchkine P, Autmizguine J. Population pharmacokinetics of ganciclovir and valganciclovir in pediatric solid organ and stem cell transplant recipients. Br J Clin Pharmacol. 2020.

Laetsch TW, Myers GDouglas, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, de Moerloose B, Davis KL, Nemecek E, et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019.

Waespe N, Mlakar SJurkovic, Dupanloup I, Rezgui MAziz, Bittencourt H, Krajinovic M, Kuehni CE, Nava T, Ansari M. A novel integrative multi-omics approach to unravel the genetic determinants of rare diseases with application in sinusoidal obstruction syndrome. PLoS One. 2023;18(4):e0281892.

Subburaj D, Ng B, Kariminia A, Abdossamadi S, Lauener M, Nemecek ER, Rozmus J, Kharbanda S, Kitko CL, Lewis VAnthony, et al. Metabolomic Identification of Alpha-Ketoglutaric Acid Elevation in Pediatric Chronic Graft-versus-Host Disease. Blood. 2021.

Ceppi F, Duval M, Leclerc J-M, Laverdiere C, Delva Y-L, Cellot S, Teira P, Bittencourt H. Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy. PLoS One. 2016;11(9):e0160310.

Mlakar SJurkovic, Uppugunduri SChakradhar, Nava T, Mlakar V, Golay H, Robin S, Waespe N, Rezgui MAziz, Chalandon Y, Boelens JJan, et al. Correction to: GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2021.

Ansari M, Uppugunduri CRao S, Ferrari-Lacraz S, Bittencourt H, Gumy-Pause F, Chalandon Y, Tiercy J-M, Schechter T, Gassas A, Doyle JD, et al. The Clinical Relevance of Pre-Formed Anti-HLA and Anti-MICA Antibodies after Cord Blood Transplantation in Children. PLoS One. 2013;8(8):e72141.

Beaufils C, Proulx C, Blincoe A, Teira P, Bittencourt H, Cellot S, Duval M, Morin M-P, De Bruycker JJacques, Couture J, et al. Case report: Success of allogeneic hematopoietic stem cell transplantation for refractory systemic-onset juvenile idiopathic arthritis. Front Med (Lausanne). 2023;10:1275927.

Truong TH, Pole JD, Bittencourt H, Schechter T, Cuvelier GDE, Paulson K, Rayar M, Mitchell D, Schultz KR, O'Shea D, et al. Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-based Analysis. Biol Blood Marrow Transplant. 2019.